Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics for alleged securities fraud. The complaint alleges that the company made false statements about its manufacturing vendor's FDA compliance and failed to disclose material risks regarding regulatory approval delays for oxylanthanum carbonate. Investors who purchased shares between December 29, 2025 and June 29, 2026 may be eligible to join the lawsuit.

10/22/2026, 10:00 AM • GlobeNewswire

UNCY FINAL DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY

Rosen Law Firm reminds investors of Unicycive Therapeutics who purchased securities between December 29, 2025 and June 29, 2026 of the November 2, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Unicycive made materially false statements regarding its third-party manufacturing vendor's FDA compliance and failed to disclose risks of regulatory delays for its oxylanthanum carbonate drug candidate.

10/21/2026, 5:32 PM • GlobeNewswire

ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs.

10/18/2026, 3:04 PM • GlobeNewswire

UNICYCIVE DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Unicycive Therapeutics for allegedly making false statements about its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. The lead plaintiff deadline is November 2, 2026. Similar lawsuits have been filed against Webull Corporation and Alphabet Inc.

10/18/2026, 11:38 AM • GlobeNewswire

Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights

Robbins LLP reminds investors of a class action lawsuit against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility to ensure FDA deficiencies were resolved. The FDA issued a Complete Response Letter in June 2026 citing the same manufacturing deficiencies as a previous CRL, causing UNCY stock to drop 39.1% to $4.69 per share. The class period covers purchases between December 29, 2025 and June 29, 2026, with a lead plaintiff deadline of November 2, 2026.

10/14/2026, 7:31 PM • GlobeNewswire

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Unicycive Therapeutics (UNCY) shareholders are urged to file claims in a securities fraud class action lawsuit. The company's stock fell 39.1% on June 30, 2026, after the FDA issued a Complete Response Letter citing the same third-party manufacturing deficiencies as a previous rejection. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.

10/14/2026, 2:40 PM • GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm is reminding investors who purchased Unicycive Therapeutics securities between December 29, 2025 and June 29, 2026 about the November 2, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Unicycive made materially false statements regarding its third-party manufacturing vendor's FDA compliance and failed to disclose risks of regulatory delays for its oxylanthanum carbonate drug candidate.

10/11/2026, 7:27 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics, Inc. (UNCY), Hims & Hers Health, Inc. (HIMS), and Beta Bionics, Inc. (BBNX) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

10/06/2026, 7:00 AM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

A securities class action lawsuit has been filed against Unicycive Therapeutics, Inc. (UNCY) for allegedly making materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims the company failed to disclose that it had not inspected the vendor's facility or audited its compliance with manufacturing practices, creating undisclosed risks of regulatory delays for its oxylanthanum carbonate drug. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

10/05/2026, 9:24 PM • GlobeNewswire

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Unicycive Therapeutics faces a securities fraud class action lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The stock fell 39.1% on the news. The lawsuit alleges the company failed to disclose that it had not inspected its manufacturing vendor's facility or audited compliance with manufacturing practices, and lacked reasonable basis to believe deficiencies were resolved. The deadline to file a lead plaintiff motion is November 2, 2026.

10/05/2026, 2:50 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Unicycive Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its third-party manufacturing vendor's FDA compliance. The lawsuit claims Unicycive failed to properly audit the vendor's facility and lacked reasonable basis for positive statements about regulatory approval prospects for oxylanthanum carbonate. Investors who purchased securities between December 29, 2025 and June 29, 2026 may be eligible to join the case.

10/05/2026, 12:00 PM • GlobeNewswire

DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Hyliion Holdings Corp., Hims & Hers Health Inc., Unicycive Therapeutics Inc., and Baidu Inc. The lawsuits allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their respective businesses. Investors have until specified deadlines in late October and November 2026 to file lead plaintiff motions.

10/01/2026, 4:00 PM • GlobeNewswire

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Unicycive Therapeutics faces a class action securities fraud lawsuit after the FDA issued a Complete Response Letter (CRL) on June 30, 2026, citing the same third-party manufacturing deficiencies as a previous rejection. The company's stock fell 39.1% following the announcement. The lawsuit alleges defendants made false statements and failed to disclose that the company had not properly audited its manufacturing vendor's compliance with FDA standards.

09/29/2026, 2:45 PM • GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Rosen Law Firm is soliciting investors for multiple securities class action lawsuits. The primary case involves Unicycive Therapeutics, which allegedly made false statements about its manufacturing vendor's FDA compliance and the regulatory approval timeline for its drug oxylanthanum carbonate. The firm is also handling class actions for FuelCell Energy and GoDaddy, with lead plaintiff deadlines approaching in November 2026.

09/28/2026, 7:16 PM • GlobeNewswire

UNCY Stockholders Have Rights – If You Lost Money Investing in Unicycive Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

A class action lawsuit was filed against Unicycive Therapeutics (UNCY) for allegedly failing to disclose that it had not inspected its third-party manufacturing vendor's facility before resubmitting a New Drug Application to the FDA. The company's stock dropped 39.1% on June 30, 2026, when the FDA issued a Complete Response Letter citing the same manufacturing deficiencies previously identified. Investors who purchased UNCY securities between December 29, 2025 and June 29, 2026 may be eligible to participate in the lawsuit.

09/25/2026, 2:57 PM • GlobeNewswire